LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

  • Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned. Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Carl Christoph Schimanski, Markus Möhler, Michael Schön, Eric Van Cutsem, Richard Greil, Wolf Otto BechsteinORCiDGND, Susanna Hegewisch-BeckerGND, Götz Peter Lothar von Wichert, Matthias Vöhringer, Michael Heike, Volker Heinemann, Marc Peeters, Stephan Kanzler, Stefan Kasper, Friedrich Overkamp, Jan Schröder, Daniel Seehofer, Frank Kullmann, Bernhard Linz, Irene SchmidtmannORCiDGND, Victoria Smith-Machnow, Ines Gockel, Hauke Lang, Peter R. GalleORCiDGND
URN:urn:nbn:de:hebis:30:3-240748
DOI:https://doi.org/doi:10.1186/1471-2407-12-144
ISSN:1471-2407
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/22494623
Parent Title (English):BMC cancer
Publisher:BioMed Central
Place of publication:London
Document Type:Article
Language:English
Date of Publication (online):2012/05/22
Date of first Publication:2012/04/11
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2012/05/22
Volume:12
Issue:144
Page Number:9
HeBIS-PPN:311001149
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0